The BLMH knockout SK-HEP-1 polyclonal cells represent a CRISPR/Cas9-edited population derived from the SK-HEP-1 human liver adenocarcinoma cell line, engineered to disrupt the BLMH gene. This polyclonal format provides a heterogeneous pool of cells with targeted gene inactivation, offering a robust loss-of-function model for interrogating BLMH-dependent processes without the selective pressures associated with clonal isolation. The knockout cell population is generated using CRISPR/Cas9-mediated gene disruption, resulting in a versatile tool for functional studies in cancer biology and drug metabolism.
SK-HEP-1 is a well-characterized cell line originally established from the ascitic fluid of a male patient diagnosed with liver adenocarcinoma. These cells display an endothelial-like phenotype and maintain malignant characteristics, including a high metastatic potential, making them a relevant in vitro system for studying hepatic tumor biology. The cell line’s origin from a metastatic site endows it with features suitable for investigating pathways involved in tumor progression, invasion, and therapeutic resistance, particularly in the context of liver-derived cancers.
BLMH encodes bleomycin hydrolase, a neutral cysteine protease that self-assembles into a functional homohexamer. Its expression is upregulated by oxidative stress through NRF2 signaling, positioning BLMH as a stress-responsive enzyme. Mechanistically, BLMH hydrolyzes the glycopeptide anticancer drug bleomycin, rendering it inactive and thereby contributing to chemoresistance. Beyond drug metabolism, BLMH processes homocysteine-thiolactone to homocysteine, playing a role in homocysteine homeostasis, and degrades amyloid-beta peptides, implicating it in Alzheimer’s disease pathology. These molecular functions link BLMH to both cancer chemotherapy outcomes and neurodegenerative processes.
In the SK-HEP-1 adenocarcinoma background, BLMH activity is particularly relevant for intrinsic and acquired resistance to bleomycin-based therapies, a common challenge in hepatic malignancies. Disruption of BLMH in this cellular context provides a physiologically meaningful model to dissect the molecular underpinnings of drug detoxification and to identify strategies for sensitizing cancer cells to treatment. Furthermore, the endothelial-like properties of SK-HEP-1 cells may allow exploration of BLMH’s role in tumor microenvironment interactions and protease-mediated regulation of metastatic behavior.
This polyclonal knockout pool is well-suited for a range of experimental applications, including bleomycin sensitivity assays to evaluate chemoresistance, protease activity measurements to quantify enzymatic function, and homocysteine metabolite analysis to study metabolic pathways. Researchers can also investigate antigen presentation and amyloid-beta degradation using western blotting, RT-qPCR, and functional degradation assays. Additional uses include high-throughput screening for modulators of BLMH activity. For further information, please contact Ascent Research.
